NOV 28, 2022 10:45 AM PST

Experimental Drug Halts Deadly Brain Cancer Growth Without Harming Brain Cells

WRITTEN BY: Annie Lennon

 

Researchers have found that blocking a certain enzyme halts the growth of a childhood brain cancer tumor. The corresponding research was conducted by a team of scientists at McMaster University and published in the journal Cancer Cell.

MYC-driven medulloblastoma (MB) is an aggressive form of childhood brain cancer that develops from neural stem cells in the cerebellum- an area of the brain at the back of the head that helps motor coordination, balance, and posture. 

MYC is the name of a group of genes often linked to the formation of cancers, including MB. MB has now surpassed leukemia as the most fatal childhood illness, with 30% of cases not responding to available treatments.

For the present study, the researchers sought to find a novel target for treating MYC-driven MB. From genetic screening and metabolomic profiling data, they identified dihydroorotate dehydrogenase (DHODH) as a potential target to treating MYC-driven MB. DHODH is an enzyme involved in building nucleotides- or DNA blocks- in the human body.

To test the potential new target, the researchers blocked DHODH on mouse models of MYC-driven MB, and compared them to controls. They found that blocking DHODH halted cancer growth, and left surrounding brain and nerve cells intact- one of the key challenges to existing treatments, including surgery, radiotherapy, and chemotherapy, which are linked to multiple side effects.  

"This potential treatment pathway will allow us to kill the weeds but save the flower of the developing brain," said first author of the study, William Gwynne, a post-doctoral researcher of the Centre for Discovery in Cancer Research, in a press release

"This DHODH treatment target is full of promise, but it will take several years before we can reach the clinical trial stage. This potential new treatment, unlike current ones, will not be toxic to the developing brain,” he concluded.

 

Sources: ScienceDirect, Cancer Cell

 

About the Author
Other
Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
DEC 21, 2022
Cannabis Sciences
Pain relief from weed - real or placebo?
Pain relief from weed - real or placebo?
Some experts believe that pain relief from cannabis is all in the user's imagination - is it real or a placebo effect?
DEC 13, 2022
Neuroscience
Neuroscience of Sex and Gender with Dr. Daphna Joel | Life of Her Mind Ep. 4
Neuroscience of Sex and Gender with Dr. Daphna Joel | Life of Her Mind Ep. 4
Dr. Daphna Joel is Professor of Psychology and Neuroscience at Tel Aviv University. Dr. Joel is a member of the School o ...
DEC 23, 2022
Chemistry & Physics
The Science Behind Holiday Specs
The Science Behind Holiday Specs
Whether young or old, anyone can enjoy those fun holiday glasses that turn pinpoints of lights into fun shapes—sno ...
DEC 24, 2022
Neuroscience
A Probiotic Microbe Could Protect Against ALS
A Probiotic Microbe Could Protect Against ALS
The microbes in our guts are closely connected to our brains, in a link known as the gut-brain axis. Scientists have now ...
DEC 29, 2022
Neuroscience
Vaping May Not Help Smokers Quit Tobacco Use
Vaping May Not Help Smokers Quit Tobacco Use
A new study, published in Tobacco Control, by George Washington University researchers found that adults who vape and sm ...
JAN 25, 2023
Technology
Researchers Use Mice to Experiment with Silica Nano-Sized Capsules Carrying Gene-Editing Tools
Researchers Use Mice to Experiment with Silica Nano-Sized Capsules Carrying Gene-Editing Tools
In a recent study published in Advanced Materials, a team of researchers at the University of Wisconsin-Madison have dev ...
Loading Comments...